-
In this issue: Some women with DVT may stop warfarin after six months; Vytorin and cancer; preventing recurrent stroke; and FDA news.
-
Although reactivation of CMV has significant adverse consequences for immunocompromised patients, such as those receiving organ transplants, the effect of CMV reactivation in critically ill immunocompetent patients is unclear.
-
Investigators at a number of university-affiliated HIV clinics around the United States conducted the Living Positively Survey to explore the experiences and attitudes of HIV+ woman toward health care, treatment, pregnancy, and family issues.
-
Resistance to oseltamivir (tamifluR) has increased in Influenza A isolates around the world at an alarming rate. Levels of resistance now range from 13% in Chile to 100% (10 of 10 isolates) in Australia.
-
Of note, this publication is a review article and not original science. Because of its efficacy and convenience, DMPA has been used by millions of women in the United States and around the world.
-
The lift study (Long-Term Intervention on Fractures with Tibolone) was a randomized, placebo-controlled multicenter trial in 22 countries of tibolone, 1.25 mg, given daily over 3 years.
-
The objective of this study was to examine and compare the clinical behavior and outcome of uterine carcinosarcoma relative to grade 3 endometrioid carcinoma.
-
Fetal fibronectin is now being used in many hospitals to separate out those with preterm contractions (PTCs) who are in true labor from those with contractions who are not (and, therefore, not requiring tocolytics or hospitalization).
-
In this issue: Some women with DVT may stop warfarin after six months; Vytorin and cancer; preventing recurrent stroke; and FDA news.
-
Newcomb and colleagues reported breast cancer mortality in the Collaborative Breast Cancer Study Cohort, a prospective cohort of 12,269 postmenopausal women from Wisconsin, Massachusetts, or New Hampshire.
